MedTrace Logo

Early Antibiotic Therapy and Vaccination

NCT04109833 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2019-09-30

No results posted yet for this study

Summary

Neonatal Sepsis is one of the most common causes of death in preterm infants. Therefore, up to 80% of very low birth weight infants receive antibiotic therapy in their first week of life. Antibiotic therapy is one of the most important influencing factors for the establishment of the intestinal microbiome, which in turn modulates neonatal immune development. In this pilot study, it will be investigated, if antibiotic therapy in the first week of life influences the vaccination response of preterm infants.

Conditions

  • Vaccination Reaction

Interventions

DRUG

ABT

any antibiotic therapy in the first week of life

Sponsors & Collaborators

  • University Hospital Tuebingen

    lead OTHER

Principal Investigators

  • Natascha Köstlin-Gille, Dr. med. · Department for Neonatology at University Hospital Tübingen

Eligibility

Min Age
24 Weeks
Max Age
28 Weeks
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-09-27
Primary Completion
2021-10-31
Completion
2021-10-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04109833 on ClinicalTrials.gov